# An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)

> **NCT02856802** · PHASE2 · COMPLETED · sponsor: **Upsher-Smith Laboratories** · enrollment: 107 (actual)

## Conditions studied

- Migraine Headaches

## Interventions

- **DRUG:** Sumatriptan 10 mg Nasal Spray
- **OTHER:** Sumatriptan Placebo Nasal Spray

## Key facts

- **NCT ID:** NCT02856802
- **Lead sponsor:** Upsher-Smith Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-11
- **Primary completion:** 2017-02-10
- **Final completion:** 2017-02-10
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2021-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02856802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02856802, "An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02856802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*